Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Br J Cancer
    November 2017
  1. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
    Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    >> Share

    October 2017
  2. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    >> Share

  3. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    >> Share

    September 2017
  4. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    >> Share

  5. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    >> Share

  6. MORRELL S, Roder D, Taylor R
    Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    >> Share

  7. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
    Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    >> Share

  8. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
    Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    >> Share

  9. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
    A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    >> Share

  10. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    >> Share

    August 2017
  11. CAPELAN M, Battisti NML, McLoughlin A, Maidens V, et al
    The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    >> Share

  12. GURVITS N, Loyttyniemi E, Nykanen M, Kuopio T, et al
    Separase is a marker for prognosis and mitotic activity in breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    >> Share

  13. ALESKANDARANY MA, Sonbul S, Surridge R, Mukherjee A, et al
    Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
    Br J Cancer. 2017 Aug 22. doi: 10.1038/bjc.2017.
    >> Share

  14. OKONJI DO, Sinha R, Phillips I, Fatz D, et al
    Comprehensive geriatric assessment in 326 older women with early breast cancer.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    >> Share

  15. SHI F, Zhang Q, Liang Z, Zhang M, et al
    One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    >> Share

  16. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    >> Share

    July 2017
  17. SMITH A, Murphy L, Zgaga L, Barron TI, et al
    Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.
    Br J Cancer. 2017 Jul 18. doi: 10.1038/bjc.2017.
    >> Share

  18. JIANG L, Luan Y, Miao X, Sun C, et al
    Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    >> Share

  19. VAN MAAREN MC, Bretveld RW, Jobsen JJ, Veenstra RK, et al
    The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival.
    Br J Cancer. 2017;117:179-188.
    >> Share

  20. WU J, Zhou XJ, Sun X, Xia TS, et al
    RBM38 is involved in TGF-beta-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    >> Share

    June 2017
  21. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    >> Share

  22. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    >> Share

  23. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    >> Share

  24. MAVROUDIS D, Saloustros E, Boukovinas I, Papakotoulas P, et al
    Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    >> Share

  25. LEVASSEUR N, Chia SK
    Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    >> Share

  26. MOSKOWITZ CS, Chou JF, Sklar CA, Barnea D, et al
    Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    >> Share

  27. CUI YX, Bradbury R, Flamini V, Wu B, et al
    MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    >> Share

  28. CHEN LL, Zhang ZJ, Yi ZB, Li JJ, et al
    MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    >> Share

    May 2017
  29. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    >> Share

    April 2017
  30. HEQUET D, Huchon C, Baffert S, Alran S, et al
    Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    >> Share

  31. KWIATKOWSKI F, Mouret-Reynier MA, Duclos M, Bridon F, et al
    Long-term improvement of breast cancer survivors' quality of life by a 2-week group physical and educational intervention: 5-year update of the 'PACThe' trial.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    >> Share

  32. ROMAN M, Quintana MJ, Ferrer J, Sala M, et al
    Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    >> Share

  33. TRAN WT, Gangeh MJ, Sannachi L, Chin L, et al
    Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
    Br J Cancer. 2017 Apr 18. doi: 10.1038/bjc.2017.
    >> Share

  34. MESCI A, Huang X, Taeb S, Jahangiri S, et al
    Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis.
    Br J Cancer. 2017 Apr 18. doi: 10.1038/bjc.2017.
    >> Share

  35. MILLER AB
    Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study'.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    >> Share

    March 2017
  36. CHIARELLI AM, Muradali D, Blackmore KM, Smith CR, et al
    Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    >> Share

  37. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    >> Share

  38. SHEN J, Liao Y, Hopper JL, Goldberg M, et al
    Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    >> Share

  39. MANDL MM, Zhang S, Ulrich M, Schmoeckel E, et al
    Inhibition of Cdk5 induces cell death of tumor-initiating cells.
    Br J Cancer. 2017;116:912-922.
    >> Share

  40. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    >> Share

  41. ROUZIER R, Uzan C, Rousseau A, Guillot E, et al
    Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NO
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    >> Share

  42. ALTUNDAG K
    Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    >> Share

  43. FUJII T, Ueno NT
    Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    >> Share

    February 2017
  44. BRESLIN S, Lowry MC, O'Driscoll L
    Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
    Br J Cancer. 2017;116:620-625.
    >> Share

  45. PINDER SE, Campbell AF, Bartlett JM, Marshall A, et al
    Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
    Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.
    >> Share

  46. CATALANO OA, Horn GL, Signore A, Iannace C, et al
    PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    >> Share

  47. PARK YM, O'Brien KM, Zhao S, Weinberg CR, et al
    Gestational diabetes mellitus may be associated with increased risk of breast cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    >> Share

  48. YIP C, Foidart P, Somja J, Truong A, et al
    MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    >> Share

  49. MORRELL S, Taylor R, Roder D, Robson B, et al
    Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    >> Share

  50. MOYNAHAN ME, Chen D, He W, Sung P, et al
    Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    >> Share

  51. DE PLACIDO S, De Angelis C, Giuliano M, Pizzi C, et al
    Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
    Br J Cancer. 2017 Feb 7. doi: 10.1038/bjc.2017.
    >> Share

  52. HANSEN MF, Jensen SO, Fuchtbauer EM, Martensen PM, et al
    High folic acid diet enhances tumour growth in PyMT-induced breast cancer.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    >> Share

    January 2017
  53. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    >> Share

  54. FUJII T, Kogawa T, Wu J, Sahin AA, et al
    Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    >> Share

  55. KAZARIAN A, Blyuss O, Metodieva G, Gentry-Maharaj A, et al
    Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    >> Share

  56. PARRA K, Valenzuela P, Lerma N, Gallegos A, et al
    Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    >> Share

  57. ROCHEFORT P, Chabaud S, Pierga JY, Tredan O, et al
    Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    >> Share

  58. SOOD D, Johnson N, Jain P, Siskos AP, et al
    CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.
    Br J Cancer. 2017;116:382-388.
    >> Share

    December 2016
  59. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    >> Share

  60. JOHNS LE, Coleman DA, Swerdlow AJ, Moss SM, et al
    Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    >> Share

  61. UUSITALO E, Kallionpaa RA, Kurki S, Rantanen M, et al
    Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    >> Share

  62. DALDORFF S, Mathiesen RM, Yri OE, Odegard HP, et al
    Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
    Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
    >> Share

    November 2016
  63. SUN J, Chia S
    Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    >> Share

  64. LAMBERTINI M, Pinto AC, Ameye L, Jongen L, et al
    The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
    Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
    >> Share

    October 2016
  65. MOLLER H, Henson K, Luchtenborg M, Broggio J, et al
    Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England.
    Br J Cancer. 2016 Oct 25. doi: 10.1038/bjc.2016.
    >> Share

  66. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    >> Share

  67. LAM SW, Frederiks CN, van der Straaten T, Honkoop AH, et al
    Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    >> Share

  68. OBIORAH I, Sengupta S, Fan P, Jordan VC, et al
    Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    >> Share

  69. COLZANI E, Clements M, Johansson AL, Liljegren A, et al
    Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    >> Share

    September 2016
  70. HOUVENAEGHEL G, Sabatier R, Reyal F, Classe JM, et al
    Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    >> Share

  71. CAMPBELL EJ, Tesson M, Doogan F, Mohammed ZM, et al
    The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    >> Share

  72. TONETTI DA, Chisamore MJ, Grdina W, Schurz H, et al
    Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    >> Share

  73. LIM E, Palmieri C, Tilley WD
    Renewed interest in the progesterone receptor in breast cancer.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    >> Share

  74. PRESTON DL, Kitahara CM, Freedman DM, Sigurdson AJ, et al
    Breast cancer risk and protracted low-to-moderate dose occupational radiation exposure in the US Radiologic Technologists Cohort, 1983-2008.
    Br J Cancer. 2016 Sep 13. doi: 10.1038/bjc.2016.
    >> Share

  75. BOSCO-LEVY P, Jove J, Robinson P, Moore N, et al
    Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    >> Share

    August 2016
  76. JONASSON JG, Stefansson OA, Johannsson OT, Sigurdsson H, et al
    Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    >> Share

  77. DE MUNCK L, de Bock GH, Otter R, Reiding D, et al
    Digital vs screen-film mammography in population-based breast cancer screening: performance indicators and tumour characteristics of screen-detected and interval cancers.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    >> Share

  78. SMITH A, Murphy L, Sharp L, O'Connor D, et al
    De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
    Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
    >> Share

    July 2016
  79. JONES ME, Schoemaker MJ, Wright L, McFadden E, et al
    Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    >> Share

  80. ZHU B, Mukherjee A, Machiela MJ, Song L, et al
    An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer.
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    >> Share

    June 2016
  81. MILLICAN-SLATER RA, Sayers CD, Hanby AM, Hughes TA, et al
    Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    >> Share

  82. PERSSON M, Simonsson M, Markkula A, Rose C, et al
    Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    >> Share

  83. GRAM IT, Little MA, Lund E, Braaten T, et al
    The fraction of breast cancer attributable to smoking: The Norwegian women and cancer study 1991-2012.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    >> Share

  84. SOGAARD M, Farkas DK, Ording AG, Sorensen HT, et al
    Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    >> Share

    May 2016
  85. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    >> Share

  86. MELVIN JC, Purushotham AD, Garmo H, Pinder SE, et al
    Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    >> Share

  87. WARSCHKOW R, Cerny T, Schmied BM, Guller U, et al
    A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction.
    Br J Cancer. 2016 May 17. doi: 10.1038/bjc.2016.
    >> Share

  88. MESEURE D, Vacher S, Lallemand F, Alsibai KD, et al
    Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
    Br J Cancer. 2016 May 12. doi: 10.1038/bjc.2016.
    >> Share

    March 2016
  89. BROWN JS, Kaye SB, Yap TA
    PARP inhibitors: the race is on.
    Br J Cancer. 2016;114:713-5.
    >> Share

  90. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
    Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Br J Cancer. 2016;114:777-86.
    >> Share

  91. PHI XA, Saadatmand S, De Bock GH, Warner E, et al
    Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
    Br J Cancer. 2016;114:631-7.
    >> Share

  92. LOUSDAL ML, Kristiansen IS, Moller B, Stovring H, et al
    Effect of organised mammography screening on stage-specific incidence in Norway: population study.
    Br J Cancer. 2016;114:590-6.
    >> Share

    February 2016
  93. THOMSON AH, McGrane J, Mathew J, Palmer J, et al
    Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.
    Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
    >> Share

    January 2016
  94. HAMY-PETIT AS, Belin L, Bonsang-Kitzis H, Paquet C, et al
    Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
    Br J Cancer. 2016;114:44-52.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016